[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hearing-loss-adult-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hearing-loss-adult-onset":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,75,98,120,147,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100582195","cochlear-implant-speech-in-noise-processing-100582195",false,"NCT06860152","Cochlear Implant Speech in Noise Processing","O15-PET Imaging of Cochlear Implant Speech in Noise Processing","Cochlear Implant subjects (enrollment is planned at N=120) - Inclusion criteria:\n\n1. Between 18 and 99 years of age.\n2. Have a cochlear implant activated for more than one year.\n3. Eligible for research under the Iowa Cochlear Implant Project VIII.\n4. Ability to understand and willingness to sign a written informed consent document.\n5. Severe hearing loss after age 16.\n\nNormal Hearing subjects (enrollment is planned at N=30) - Inclusion criteria:\n\n1. Between 18 and 99 years of age.\n2. Have age typical hearing.\n3. Eligible for research under the Iowa Cochlear Implant Project VIII.\n4. Ability to understand and willingness to sign a written informed consent document.\n\nExclusion criteria (all groups):\n\n1. Medical history includes seizure disorder, head injury, neurologic, metabolic, cardiovascular disease, or previous cerebrovascular event (unless approved by PI).\n2. Female self-reporting pregnancy. A urine pregnancy test will be performed prior to injection of the radiopharmaceutical.\n3. Currently taking medications which may affect cerebral blood flow (e.g., papaverine, ginkgo biloba, acetazolamide).\n4. Uncontrolled intercurrent illness that would limit compliance with study requirements per investigator.","ALL","18 Years","99 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study will help us in understanding the neural mechanisms by which listeners with a cochlear implant detect speech in noisy environments.",[27,28,29],"Hearing Loss, Adult-Onset","Speech Intelligibility","Hearing Loss, Extreme","RECRUITING","2026-05-11",{"date":33,"type":34},"2026-05-14","ACTUAL",{"date":36,"type":34},"2024-11-14",{"date":38,"type":21},"2028-03-31",{"name":40,"class":41},"Craig D. Workman, PhD","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100641014","ai-assisted-diagnosis-triage-and-assessment-of-hearing-loss-and-tinnitus-100641014","NCT07586098","AI-assisted Diagnosis, Triage and Assessment of Hearing Loss and Tinnitus","Artificial Intelligence for the Automated Diagnosis, Triage, and Assessment of Patients With Hearing Loss and Tinnitus: A Pilot Comparative Study With Clinical Evaluation by Otolaryngologists","Inclusion Criteria:\n\n* Patients assessed in the RCHT virtual hearing loss and tinnitus clinic.\n* Presenting symptoms of hearing loss and\u002For tinnitus.\n* Ability to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Patients unable to provide informed consent.\n* Patients without sufficient English proficiency where translation services cannot be arranged.\n* Cases where data quality is insufficient for analysis.",{"count":51,"type":21},1500,"1 Year","OBSERVATIONAL","Hearing loss affects approximately 11 million people in the UK, while tinnitus impacts around 7 million. Both conditions can significantly reduce quality of life and are linked to poorer mental health and employment challenges. Each year, tinnitus alone accounts for more than one million GP appointments, and patients referred to hospital ear, nose and throat (ENT) services often face long delays, sometimes exceeding a year, before their first assessment.\n\nTo address this demand, the Royal Cornwall Hospitals NHS Trust has developed a virtual ENT clinic. Patients undergo a validated hearing test in person and complete online questionnaires. Clinicians then review these data to determine next steps, which may include discharge with advice, referral for imaging, or a face-to-face consultation. Initial trials demonstrated that the majority of patients could be managed virtually, substantially reducing waiting times. However, clinicians must still review every case, limiting capacity for patients who require direct care.\n\nThis project builds on the virtual clinic by introducing artificial intelligence (AI) to support the assessment process. Using explainable AI methods, the system will be trained to replicate clinician-level decision-making while providing transparent reasoning for its recommendations. The study will evaluate how closely AI-generated outcomes align with clinician assessments, with all cases continuing to receive a clinician's final review. Clinicians will not be aware of the recommendations produced by the AI tool, but the study aims to measure how concordant AI recommendations are with clinician assessments.\n\nIf the AI tool's clinical recommendations closely align with clinician recommendations (the gold standard for care), the AI tool could be introduced as a clinical recommendation assistant tool, streamlining the triage and management of hearing loss and tinnitus, enabling clinicians to focus on complex cases, accelerating access to care, and improving efficiency.",[27,56],"Tinnitus",[58,59,56,60,61,62,63,64,65],"Artificial Intelligence","Hearing Loss","Clinical Decision Support Systems","Computerized","Telemedicine","Otolaryngology","Patient Satisfaction","Feasibility Studies","NOT_YET_RECRUITING","2026-05-07",{"date":33,"type":34},{"date":70,"type":21},"2026-05-30",{"date":72,"type":21},"2027-08-31",{"name":74,"class":41},"Royal Cornwall Hospitals Trust",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100580647","use-of-airpod-pros-as-assistive-technology-100580647","NCT06840015","Use of Airpod Pros as Assistive Technology","Inclusion Criteria:\n\n* Adults aged 18 to 60 years.\n* Fluent English speakers.\n* Mild-to-moderate hearing loss confirmed by a pure-tone hearing test (average hearing threshold screening 25 to 55 dB HL across octave frequencies from 250 to 8000 Hz).\n* Individuals with no prior hearing aid experience for a year.\n\nExclusion Criteria:\n\n* Normal hearing.\n* Hearing loss worse than moderate.\n* Neurological, psychiatric, or ophthalmological conditions that might alter the pupil response.\n* Non-fluent English speakers.\n* Individuals with prior hearing aid experience more than a year.",true,"60 Years",{"count":84,"type":21},24,[24],"The goal of this study is to investigate the suitability and effectiveness of the AirPod Pro 2nd and 3rd generation (AP) as hearing assistive technology for individuals with mild-to-moderate hearing loss when listening in noisy environments. Researchers will compare four types of assistive technology: hearing aids (HAs), AP, dedicated wireless remote microphones, and Smartphone wireless remote microphone.\n\nThe main questions it aims to answer are:\n\n* Which assistive technology provides the greatest benefit for speech recognition in noisy environments?\n* How do these devices impact listening effort, as measured by reaction time in a dual-task activity and changes in pupil size?\n* What are participants' preferences for each device based on how easy it is to understand speech and their overall satisfaction? Participants will visit the lab for a single 3-hour session. They will listen to sentences using each device and repeat what they hear. During this task, their reaction times for the secondary task and changes in pupil size will be measured.",[27,88],"Hearing Aids",[90,88,59],"AirPod Pro (AP)",{"date":31,"type":34},{"date":93,"type":34},"2025-07-01",{"date":95,"type":21},"2026-07",{"name":97,"class":41},"The University of Texas at Dallas",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100615119","hearing-loss-and-brain-health-study-100615119","NCT07288463","Hearing Loss and Brain Health Study","Inclusion Criteria:\n\n* Age \\>= 50 years\n* Known APOE status\n* Bilateral mild to moderate sensorineural hearing loss\n* No current use of hearing aids or cochlear implants\n* No diagnosis of dementia and able to provide informed consent\n* Able to complete questionnaires and follow instructions in English\n* Willing and able to comply with study procedures, follow-up visits, and hearing-aid use\n\nExclusion Criteria:\n\n* Clinical diagnosis of dementia\n* Severe or profound hearing loss\n* Self-reported congenital hearing loss\n* Absence of an ear canal due to medical conditions or prior surgical procedures\n* unwillingness to wear OTC hearing aids regularly (\\>=4 hours\u002Fday)\n* medical contraindication to use hearing aids (e.g., actively draining ear)\n* Known retrocochlear pathology\n* Severe uncorrected visual impairment or significant manual dexterity limitations that prevent handling the device","50 Years",{"count":106,"type":21},40,[24],"Hearing loss is a prevalent and modifiable risk factor for cognitive decline and dementia in older adults, yet access to hearing care remains limited. Over-the-counter (OTC) hearing aids represent a promising and scalable strategy to expand access, particularly for individuals at elevated risk for dementia who may benefit most from earlier intervention. This pilot study aims to evaluate the feasibility and acceptability of OTC hearing aid use among older adults. Participants aged ≥50 years will undergo standardized hearing screening to identify bilateral, mild-to-moderate hearing loss. Eligible participants will be randomized to one of two sequences: (1) immediate intervention: 3-mo using OTC hearing aids or (2) waitlist control: 3-mo without devices followed by OTC hearing aid use after 3 months. Feasibility outcomes include study enrollment and retention, protocol adherence, and average daily device use determined by data-logging. Acceptability outcomes will be assessed using the International Outcome Inventory for Hearing Aids (IOI-HA), device satisfaction ratings, and participant intention to continue hearing-aid use. Hearing outcomes include validated questionnaires on hearing and listening efforts. Findings will inform the design of larger trials aimed at improving access to hearing care and promoting cognitive health.",[27,110],"Dementia","2026-05-06",{"date":113,"type":34},"2026-05-08",{"date":115,"type":21},"2027-07-01",{"date":117,"type":21},"2031-06-30",{"name":119,"class":41},"University of Southern California",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100499710","hearing-healthcare-assessment-in-rural-communities-100499710","NCT05786794","Hearing Healthcare Assessment in Rural Communities","Hearing Healthcare Assessment in Rural Communities (HHARC)","HHARC","Inclusion Criteria:\n\n* Age 18 years or older\n* Able to speak, understand, and read English.\n* Patient of a participating primary care clinic\n\nExclusion Criteria:\n\n-Under 18",{"count":129,"type":21},500,[24],"Adult hearing loss in is the third most common chronic health condition in the United States. Adults living in rural areas face a higher risk of experiencing hearing loss, and more difficulty receiving testing and treatment than adults in urban settings. The goal of this clinical trial is to develop and test a community-based hearing healthcare patient navigation program in rural Kentucky. The main question this study aims to answer is:\n\n-Can the number of rural adults receiving diagnostic hearing tests be increased?",[27,133],"Hearing Loss, Age-Related",[135,136,137],"Patient Navigator","Adult Hearing Screening","Adult Hearing Loss","2026-05-01",{"date":111,"type":34},{"date":141,"type":34},"2024-08-08",{"date":143,"type":21},"2026-07-31",{"name":145,"class":41},"Matthew Bush, MD",9,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":42},"100610329","hearing-aid-benefit-in-real-world-noisy-environments-100610329","NCT07226167","Hearing Aid Benefit in Real-World Noisy Environments","Evaluating the Impact of Hearing Aid Signal Enhancement Algorithms in Real-World Contexts","Inclusion Criteria:\n\n* Over 18 years old\n* Symmetrical, bilateral, adult onset, sensorineural hearing loss\n* Experienced hearing aid users (\\> 3 months)\n\nExclusion Criteria:\n\n* Under 18 years old\n* Conductive or mixed hearing loss\n* Asymmetrical or unilateral hearing loss\n* Pre-lingual or childhood hearing loss onset\n* No hearing aid experience",{"count":155,"type":21},45,[24],"Researchers are doing this study to understand why hearing aids often work well in controlled laboratory settings but don't provide the same level of benefit in everyday noisy environments. The questions they hope to answer are:\n\n* What factors contribute to hearing aid benefit in noisy environments\n* What factors limit hearing aid benefit\n* How do real-world factors interact with common hearing aid settings\n\nParticipants will complete:\n\n* Hearing and listening tests\n* Memory and attention assessment\n* Surveys on their Smartphone",[159,160,27],"Hearing Aid","Hearing Loss, Bilateral Sensorineural","2026-02-20",{"date":163,"type":34},"2026-02-24",{"date":165,"type":34},"2026-02-19",{"date":167,"type":21},"2027-01",{"name":169,"class":41},"University of Wisconsin, Madison",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":199},"100612354","evaluation-of-performances-clinical-benefits-and-safety-of-the-audiocap-connected-hearing-rehabilitation-device-for-improving-audibility-in-hearing-impaired-people-in-the-context-of-ce-marking---audiocap-2-100612354","NCT07252492","Evaluation of Performances, Clinical Benefits and Safety of the 'Audiocap' Connected Hearing Rehabilitation Device for Improving Audibility in Hearing-impaired People in the Context of CE Marking - AUDIOCAP-2","Evaluation of Performances, Clinical Benefits and Safety of the 'Audiocap' Connected Hearing Rehabilitation Device for Improving Audibility in Hearing-impaired People in the Context of CE Marking","AUDIOCAP-2","Inclusion Criteria:\n\n1. Subjects presenting one or more of the following criteria: a.Subject with mild to moderate hearing loss (20dB to 50dB average at 500, 1000, 2000, and 4000 Hz) in the better ear according to WHO standards, \u002F b. Subject with a speech reception threshold (SRT) in quiet exceeding 30dB, corresponding to the minimum speech level required to achieve 50% recognition in silence (HAS eligibility criteria for hearing aid reimbursement), \u002F c. Subject with significant degradation of speech intelligibility in noise, defined as a speech-to-noise ratio (SNR) deviation greater than 3dB compared to normative reference values (HAS eligibility criteria for hearing aid reimbursement), \u002F d.Subject with high-frequency hearing loss greater than 30dB from 2000 Hz onwards, associated with a speech reception threshold exceeding 30dB in quiet and\u002For a significantly degraded speech intelligibility in noise (HAS eligibility criteria for hearing aid reimbursement).\n2. Subjects eligible for first hearing aid.\n3. Subjects over 18 years of age. French-speaking subjects.\n\n5\\. Subjects affiliated with a social security scheme. 6. Subjects who are not subject to another medical option, without external pathology and excluding implants.\n\n7\\. Subjects who have signed an informed consent. 8. Subjects available for the study.\n\nExclusion Criteria:\n\n1. Subject deprived of his\u002Fher liberty by a judicial or administrative decision\n2. Subject with severe psychiatric disorder\n3. Subject admitted to a health or social care establishment\n4. Subject not able to give consent\n5. Adults under guardianship or trusteeship.\n6. Subjects with disabling tinnitus that are not suitable for adaptation (THI\\>56).\n7. Subjects eligible for a cochlear implant.\n8. Subjects not able to participate in the study according to the investigator.\n9. Subjects with acute and chronic suppurative otitis media, congenital ear atresia, or any type of ear discharge.\n10. Subjects with congenital atresia of external ear or deformity of any part of the ear canal.\n11. Subjects with deafness that is unstable and with a degree of hearing loss often fluctuating.\n12. Subjects with persistent headaches, dizziness, earaches, or other symptoms that are not suitable for adaptation.\n13. Subjects with sudden onset of hearing loss within the past 3 months, rapid progressive deafness, unilateral hearing loss or other acute ear disease.\n14. Subjects with effusion (secretions\u002F discharge) in the ear and\u002For frequent purulence (pus).\n15. Subjects with central deafness (central nervous system) or non-organic deafness.\n16. Subjects with acute otitis extrema and tympanitis.\n17. Subjects who are allergic to materials of the device.",{"count":179,"type":21},100,[24],"The goal of this clinical trial is the evaluation of performances, clinical benefits and safety of the 'Audiocap' connected hearing rehabilitation device for improving audibility in hearing-impaired people.\n\nThe main question it aims to answer is to demonstrate, after one month's use of the Audiocap connected hearing aid, that the audiological gain for the patient is better than with a placebo hearing aid.\n\nPlacebo hearing aid is a Audiocap connected hearing aid with a 'NONE' setting (flat frequency response for the patient (equivalent to not wearing hearing aid).\n\nParticipants will be first-time hearing aid users, eligible for hearing aid fitting, and adults according to French legislation (18 years and older).",[27,159],[184,185,186,187,188],"Aides auditives","Prothèses auditives","Perte auditive","Appareillage audition","Adulte audition","2025-11-24",{"date":191,"type":34},"2025-11-26",{"date":193,"type":34},"2025-09-10",{"date":195,"type":21},"2027-09",{"name":197,"class":198},"Archean Technologies","INDUSTRY",4]